Accessibility StatementSkip Navigation NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or c ...

Core Viewpoint - SelectQuote Inc. is under legal scrutiny due to allegations of deceptive sales practices related to its Medicare Advantage plans, leading to a significant drop in its stock price and a class-action lawsuit from investors [1][4][5]. Legal Allegations - The lawsuit, Pahlkotter v. SelectQuote Inc. et al., claims that SelectQuote misled investors about its business model and regulatory risks from September 9, 2020, to May 1, 2025 [2][5]. - Allegations include that SelectQuote misrepresented its sales practices, promoting "unbiased advice" while actually steering customers towards higher-commission plans and accepting illegal kickbacks [3][7]. Market Impact - Following the DOJ's intervention, SelectQuote's stock price fell nearly 20% on May 1, 2025, and has since declined over 40% in the past six months, reflecting investor concerns about legal exposure and reputational damage [4][5]. Investigative Actions - Hagens Berman is investigating whether SelectQuote's revenue was artificially inflated through deceptive practices, indicating that the DOJ's involvement elevates the situation to a serious federal matter [6][8].

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices [1][2][4] - MoonLake's stock experienced a significant decline of 89.9% on September 29, 2025, following the announcement of disappointing results from its VELA-2 trial, which failed to achieve statistical significance [1][6] Investigation Details - The law firm is reaching out to investors who purchased or acquired MoonLake shares and suffered losses, encouraging them to discuss their legal rights and options [1][3] - The investigation is focused on whether the company misled investors regarding its trial results and overall business practices [1][2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in complex litigation [4] - The firm operates in multiple states, including New York, South Carolina, and California, and has a track record in commercial and securities litigation [4]

Shareholders who purchased shares of FLYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: Â July 15, 2025 to August 14, 2025 DEADLINE: November 7, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The revenue goals shared by Fly-E had no basis in reality when compared to its actual performance. T ...

Core Viewpoint - DJS Law Group is investigating claims against MoonLake Immunotherapeutics for potential violations of securities laws, particularly related to misleading statements about its VELA-2 clinical trial [1][2]. Investigation Details - The investigation centers on whether MoonLake made misleading statements or failed to disclose critical information to investors. The company's communications regarding the VELA-2 clinical trial were deemed overly optimistic until September 29, 2025, when it announced that unexpected events in the placebo group prevented the study from achieving statistical significance in its primary endpoint, resulting in a 90% decline in share value [2]. Company Background - MoonLake Immunotherapeutics is a publicly traded company on NASDAQ under the ticker MLTX. The company is currently facing scrutiny due to the recent developments in its clinical trial results [1]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing sophisticated hedge funds and alternative asset managers. The firm emphasizes the importance of protecting investor rights and maximizing returns through legal advocacy [4].

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Why Is MoonLake being Investigated?MoonLake is a clinical stage biotechnology company focusing on therapies to address inflammato ...

LOS ANGELES--(BUSINESS WIRE)--MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX. ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar. ...

LOS ANGELES--(BUSINESS WIRE)---- $MLTX--MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm. ...

SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with skin disease (hidradenitis suppurative or “HS”). The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled inv ...